Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Durvalumab + Tremelimumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA-approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with platinum-based chemotherapy as neoadjuvant therapy followed by surgery and adjuvant Imfinzi (durvalumab) in patients with resectable non-small cell lung cancer, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with carboplatin plus paclitaxel followed by single-agent Imfinzi (durvalumab) in adult patients with mismatch repair deficient endometrial cancer (FDA.gov). |
| Tremelimumab | Imjudo | CP-675,206|Ticilimumab|CP-675206 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH6 negative | stomach cancer | sensitive | Durvalumab + Tremelimumab | Guideline | Actionable | Imfinzi (durvalumab), in combination with Imjudo (tremelimumab, is included in guidelines as neoadjuvant therapy for patients with gastric cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | gastroesophageal junction adenocarcinoma | sensitive | Durvalumab + Tremelimumab | Guideline | Actionable | Imfinzi (durvalumab), in combination with Imjudo (tremelimumab), is included in guidelines as neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | stomach cancer | sensitive | Durvalumab + Tremelimumab | Guideline | Actionable | Imfinzi (durvalumab), in combination with Imjudo (tremelimumab, is included in guidelines as neoadjuvant therapy for patients with gastric cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | gastroesophageal junction adenocarcinoma | sensitive | Durvalumab + Tremelimumab | Guideline | Actionable | Imfinzi (durvalumab), in combination with Imjudo (tremelimumab), is included in guidelines as neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03529422 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Active, not recruiting | USA | 0 |
| NCT03373760 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | Completed | USA | 0 |
| NCT05239169 | Phase II | Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | Active, not recruiting | DEU | 0 |
| NCT04625699 | Phase II | Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | Withdrawn | 0 | |
| NCT05701488 | Phase I | Durvalumab + Tremelimumab | SIRT With Tremelimumab and Durvalumab for Resectable HCC | Recruiting | USA | 0 |
| NCT05932199 | Phase Ib/II | Durvalumab + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Recruiting | USA | 0 |
| NCT02879318 | Phase II | Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma | Active, not recruiting | CAN | 0 |
| NCT05000710 | Phase II | Durvalumab Durvalumab + Tremelimumab Tremelimumab | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung) | Recruiting | ISR | 0 |
| NCT03212469 | Phase Ib/II | Durvalumab + Tremelimumab | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) | Active, not recruiting | FRA | 0 |
| NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
| NCT06680739 | Phase II | Durvalumab Durvalumab + Tremelimumab | Single cEll pRofiling PErsistaNce To ImmuNothErapy (SERPENTINE) | Recruiting | ESP | 0 |
| NCT05301842 | Phase III | Durvalumab + Lenvatinib + Tremelimumab Durvalumab + Tremelimumab | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BRA | BEL | 15 |
| NCT03275597 | Phase I | Durvalumab + Tremelimumab | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | Terminated | USA | 0 |
| NCT03452332 | Phase I | Durvalumab + Tremelimumab | Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer | Completed | USA | 0 |
| NCT02716805 | Phase I | Durvalumab + Tremelimumab | Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant | Terminated | USA | 0 |
| NCT02261220 | Phase I | Durvalumab + Tremelimumab | A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
| NCT05380713 | Phase II | Durvalumab + Tremelimumab Cyclophosphamide + Durvalumab + Tremelimumab | --- SMARTEST Trial--- | Recruiting | CAN | 0 |
| NCT02549651 | Phase I | Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) | Completed | USA | IRL | GBR | FRA | 0 |
| NCT04238637 | Phase II | Durvalumab Durvalumab + Tremelimumab | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | Recruiting | DEU | 0 |
| NCT03598816 | Phase II | Durvalumab + Tremelimumab | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma | Withdrawn | 0 | |
| NCT05027425 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | Recruiting | USA | 0 |
| NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
| NCT03075527 | Phase II | Durvalumab + Tremelimumab | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | Suspended | USA | 0 |
| NCT02536794 | Phase II | Durvalumab + Tremelimumab | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | Completed | USA | 0 |
| NCT06058663 | Phase I | Durvalumab + Tremelimumab | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
| NCT03057106 | Phase II | Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium | Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Active, not recruiting | CAN | AUS | 0 |
| NCT03638141 | Phase II | Durvalumab + Tremelimumab | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | Completed | USA | 0 |
| NCT03288532 | Phase III | Durvalumab Durvalumab + Tremelimumab | Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) | Recruiting | GBR | 0 |
| NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) | Active, not recruiting | USA | POL | HUN | GBR | DEU | BRA | BGR | 12 |
| NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
| NCT03132467 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer | Completed | USA | 0 |
| NCT03430895 | Phase II | Durvalumab + Tremelimumab | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | Completed | USA | 0 |
| NCT03618134 | Phase Ib/II | Durvalumab Durvalumab + Tremelimumab | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | Terminated | USA | 0 |
| NCT05383001 | Phase II | Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) | Withdrawn | DEU | 0 |
| NCT03704480 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) | Active, not recruiting | FRA | 0 |
| NCT02821754 | Phase Ib/II | Durvalumab + Tremelimumab | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | Completed | USA | 0 |
| NCT04430452 | Phase II | Durvalumab Durvalumab + Tremelimumab | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition | Recruiting | USA | 0 |
| NCT03482102 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | Recruiting | USA | 0 |
| NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Completed | USA | 0 |
| NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |
| NCT02000947 | Phase Ib/II | Durvalumab + Tremelimumab | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 2 |
| NCT03410615 | Phase II | Durvalumab + Tremelimumab Cisplatin Durvalumab | Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC | Active, not recruiting | ITA | ESP | CAN | BEL | 0 |
| NCT03122509 | Phase II | Durvalumab + Tremelimumab | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | Completed | USA | 0 |
| NCT02794883 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Completed | USA | 0 |
| NCT04073160 | Phase I | Durvalumab Durvalumab + Tremelimumab | TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) | Withdrawn | USA | 0 |
| NCT03784066 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) | Active, not recruiting | BEL | 0 |
| NCT04397003 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT05440864 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) | Recruiting | ITA | ESP | CAN | 0 |
| NCT05120622 | Phase Ib/II | Durvalumab + Tremelimumab | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau) | Withdrawn | CAN | 0 |
| NCT06526104 | Phase II | Durvalumab + Tremelimumab | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | Not yet recruiting | USA | 0 |
| NCT04817826 | Phase II | Durvalumab + Tremelimumab | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY) | Recruiting | ITA | 0 |
| NCT01975831 | Phase I | Durvalumab + Tremelimumab | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | Completed | USA | 0 |
| NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 6 |
| NCT02369874 | Phase III | Durvalumab + Tremelimumab Durvalumab | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Completed | USA | ROU | POL | ITA | ISR | HUN | HRV | FRA | ESP | DEU | CZE | BRA | BGR | BEL | AUS | ARG | 8 |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
| NCT03624231 | Phase II | Durvalumab Durvalumab + Tremelimumab | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) | Completed | DEU | 0 |
| NCT03994393 | Phase II | Durvalumab + Tremelimumab | Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE) | Active, not recruiting | AUS | 1 |
| NCT02812420 | Phase I | Durvalumab + Tremelimumab | Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy | Active, not recruiting | USA | 0 |
| NCT03837899 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab for Pediatric Malignancies | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT03005002 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | Completed | USA | 0 |
| NCT04159974 | Phase II | Durvalumab Durvalumab + Tremelimumab | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) | Active, not recruiting | DEU | 0 |
| NCT03084471 | Phase III | Durvalumab + Tremelimumab Durvalumab | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) | Completed | USA | NLD | ITA | GBR | FRA | DEU | CAN | 1 |
| NCT03122496 | Phase I | Durvalumab + Tremelimumab | Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | Completed | USA | 0 |
| NCT03802747 | Phase I | Durvalumab + Tremelimumab Durvalumab | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Withdrawn | 0 | |
| NCT03237377 | Phase II | Durvalumab + Tremelimumab Durvalumab | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT03283605 | Phase Ib/II | Durvalumab + Tremelimumab | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | Active, not recruiting | CAN | 0 |
| NCT03158064 | Phase II | Durvalumab + Tremelimumab | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | Active, not recruiting | USA | 0 |
| NCT03522584 | Phase Ib/II | Durvalumab + Tremelimumab | Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT03150836 | Phase II | Durvalumab Durvalumab + Tremelimumab | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | Withdrawn | USA | 0 |
| NCT04605731 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | Recruiting | USA | 0 |
| NCT04522544 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design | Recruiting | DEU | 0 |
| NCT03144778 | Phase I | Durvalumab Durvalumab + Tremelimumab | Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) | Completed | USA | 0 |
| NCT02639026 | Phase I | Durvalumab + Tremelimumab | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | Completed | USA | 0 |
| NCT03206073 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Completed | USA | 0 |
| NCT03204812 | Phase II | Durvalumab + Tremelimumab | Tremelimumab + Durvalumab Chemotherapy Naive CRPC | Completed | USA | 0 |
| NCT03911557 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | Active, not recruiting | USA | 0 |
| NCT02542293 | Phase III | Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) | Active, not recruiting | USA | TUR | SWE | ROU | POL | ISR | GRC | GBR | FIN | DNK | BRA | BGR | ARG | 16 |
| NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | 7 |
| NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT02870920 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies | Completed | CAN | 0 |
| NCT03015129 | Phase II | Durvalumab Durvalumab + Tremelimumab | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Completed | USA | 0 |
| NCT03130764 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | Withdrawn | 0 | |
| NCT03026062 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Combo Versus Sequential | Active, not recruiting | USA | 0 |
| NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
| NCT03116529 | Phase Ib/II | Durvalumab + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS) | Terminated | USA | 0 |
| NCT02938793 | Phase II | Durvalumab + Tremelimumab | Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | Recruiting | USA | 0 |
| NCT02527434 | Phase II | Durvalumab + Tremelimumab Durvalumab | Study of Tremelimumab in Patients With Advanced Solid Tumors | Completed | USA | POL | NLD | BEL | 1 |
| NCT02788773 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | CAN | 0 |
| NCT05883644 | Phase III | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA) | Recruiting | USA | ITA | FRA | ESP | DEU | 5 |
| NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Active, not recruiting | USA | TUR | POL | NLD | ITA | GBR | ESP | DEU | CZE | CAN | BEL | ARG | 7 |
| NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03601455 | Phase II | Durvalumab + Tremelimumab Durvalumab | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
| NCT06109272 | Phase II | ABBV-151 + Budigalimab Atezolizumab + Bevacizumab Durvalumab + Tremelimumab | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | Recruiting | USA | ITA | FRA | ESP | 2 |
| NCT03472274 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) | Completed | ESP | 0 |
| NCT02592551 | Phase II | Durvalumab + Tremelimumab Durvalumab | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | Completed | USA | 0 |
| NCT06045975 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) | Recruiting | FRA | 0 |
| NCT03277482 | Phase I | Durvalumab + Tremelimumab Durvalumab | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Terminated | USA | 0 |
| NCT03298451 | Phase III | Sorafenib Durvalumab + Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BRA | 10 |
| NCT02762006 | Phase I | Durvalumab + Tremelimumab | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | Completed | USA | 0 |
| NCT05345678 | Expanded access | Durvalumab + Tremelimumab | Himalaya Early Access Program | Approved for marketing | USA | 0 |
| NCT03101475 | Phase II | Durvalumab + Tremelimumab | Synergism of Immunomodulation and Tumor Ablation (ILOC) | Completed | SWE | NLD | FRA | DEU | CHE | AUT | 0 |
CKB BOOST